Bioanalysis and clinical pharmacokinetics of antiretroviral agents in HIV-infected individuals

Conclusions

The research described in this thesis has given us more insight into the various aspects of the clinical pharmacokinetic behaviour of antiretroviral agents in HIV-infected individuals. Especially our knowledge of the pharmacokinetics of zidovudine has been enhanced, but data for didanosine and zalcitabine are still scarce. In all situations, the pharmacokinetics in subgroups of patients may be altered, also as a result of drug interactions. The next years special attention should be paid to pharmacokinetic-pharmaco-dynamic relationships. The above described research has created a basis for this kind of investigation.